Adaptimmune’s novel cancer treatment posts promising early results

Damian Garde

Adaptimmune's pioneering approach to immunotherapy has charted some impressive in a small study. And while the biotech is quick to point out that it's days yet, the data underscore the potential of a therapy that has convinced GlaxoSmithKline to bet up to $ 350 million on its future.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS